Hansa Biopharma AB (HNSA) — Capital Reinvestment Ratio

Latest as of September 2020: 0.14x

Hansa Biopharma AB (HNSA) has a Capital Reinvestment Ratio of 0.14x as of September 2020, meaning it reinvests 0% of its operating cash flow (Skr4.83 Million) in capital expenditures (Skr683.00K). Check HNSA intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.14x

Capex / Operating Cash Flow

Operating Cash Flow

Skr4.83 Million

SEK

Capital Expenditures

Skr683.00K

SEK

Data as of

Sep 2020

Most recent filing

Annual Capital Reinvestment Ratio for Hansa Biopharma AB (None–None)

Year-by-year Capital Reinvestment Ratio for Hansa Biopharma AB from None to None. See Hansa Biopharma AB free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.

Year	Reinvestment Ratio	Operating CF (SEK)	Capital Expenditures	YoY Change

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow